CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Caribou Biosciences, Inc. (CRBU) is rated D (1.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B (3.4) | D+ (1.7) | D+ (1.6) | F (0.5) | F (0.0) | D (1.4) |
| 2026-11-04 | B (3.4) | D+ (1.6) | D+ (1.7) | D- (1.0) | F (0.0) | D+ (1.5) |
| 2026-10-28 | B (3.3) | D+ (1.5) | D+ (1.7) | D- (0.9) | F (0.0) | D (1.5) |
| 2026-10-21 | B (3.3) | D+ (1.5) | D+ (1.7) | D- (0.9) | F (0.0) | D (1.5) |
| 2026-10-14 | B (3.3) | D+ (1.5) | D+ (1.7) | D- (0.9) | F (0.0) | D (1.5) |